Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Eli Lilly Will Bear The Cost Of A $35 Price Cap On All Copays For Its Insulins
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
